logo
Not Tonight, Honey... I'm Allergic to Your Spunk

Not Tonight, Honey... I'm Allergic to Your Spunk

Yahoo17 hours ago
Allergic reactions to semen are, unfortunately, very real.
In an essay for The Conversation, reproductive science specialist Michael Carroll of the UK's Manchester Metropolitan University explained that allergic reactions to seminal fluid can manifest as a nasty response to a partner's ejaculate, or even your own.
The most common semen allergy is what's known as "seminal plasma hypersensitivity" or SPH, in which women who have sex with men react to proteins in seminal plasma, the goopy stuff that makes up spunk. In other words, it's the seminal fluid that's to blame, not the sperm itself — but the symptoms are very real, ranging from irritating vulvar itching and painful vaginal burning to anaphylactic shock.
Bottom line? A lot of people might be suffering from this and not even know it. If you might be, doctors recommend either using condoms, taking antihistamines before sex, taking anti-inflammatory medications after sex, or desensitization therapy involving exposure of diluted semen to the skin.
"If sex routinely leaves you itchy, sore or unwell — and condoms help — you might be allergic to semen," Carroll wrote.
First documented nearly 60 years ago when a woman had to be hospitalized for her "violent allergic reaction" to sex, SPH is still, the reproductive expert wrote, often underdiagnosed. Until the year 1997, the medical establishment thought that fewer than 100 women had ever experienced the allergy, but a seminal — sorry — study that year found that nearly 12 percent of postcoital illnesses could be attributed to SPH. (Regrettably, there does not appear to be any formal inquiry whether men who have sex with men can have SPH, though there does appear to be anecdotal evidence that it does.)
About 15 years later, Carroll conducted an informal survey that found the same rate of probable SPH, though he found that the cases had often gone misdiagnosed as sexually transmitted illnesses, yeast infections, or even run-of-the-mill "sensitivity." Given that its symptoms mirror some of those illnesses, it's not hard to see why.
Along with being allergic to one's partner's semen, a separate condition known post-orgasmic illness syndrome (POIS) affects men who are allergic to their own skeet. With only 465 documented cases as of 2024, POIS can cause flu-like symptoms like fatigue and muscle aches immediately after ejaculation — and doctors are stumped as to its cause. Like SPH, both antihistamines and desensitization are recommended for POIS, as is hormonal therapy.
Speaking about SPH specifically, Carroll noted that more often than not, "sex-related symptoms often go unspoken."
"Embarrassment, stigma, and a lack of awareness among doctors mean that many women suffer in silence," the reproductive scientist said.
More on weird sex stuff: Hanky Panky With Naughty AI Still Counts as Cheating, Therapist Says
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Schizophrenia Drugs Market Size, Share & Trends Analysis Report 2025-2030 - Innovative Therapies Lead the Schizophrenia Drugs Industry Amid Unmet Needs
Schizophrenia Drugs Market Size, Share & Trends Analysis Report 2025-2030 - Innovative Therapies Lead the Schizophrenia Drugs Industry Amid Unmet Needs

Yahoo

time28 minutes ago

  • Yahoo

Schizophrenia Drugs Market Size, Share & Trends Analysis Report 2025-2030 - Innovative Therapies Lead the Schizophrenia Drugs Industry Amid Unmet Needs

Schizophrenia Drugs Market Dublin, July 07, 2025 (GLOBE NEWSWIRE) -- The "Schizophrenia Drugs Market Size, Share & Trends Analysis by Drug Class (Second- Generation Antipsychotics, Third-Generation Antipsychotics), Route of Administration, Distribution Channel, and Region with Growth Forecasts, 2025-2030" report has been added to Schizophrenia Drugs Market was valued at USD 8.19 billion in 2024, and is projected to reach USD 11.20 billion by 2030, rising at a CAGR of 5.60%. The schizophrenia market is anticipated to be collectively driven by improved drug delivery technologies, availability of Long-Acting Injectables (LAIs) and increase in patients seeking treatment. The major features assisting uptake of novel drugs would be fast onset of action, accessibility to patients, efficiency and high patient compliance. Increasing awareness among patients and physicians in the field of mental health, particularly schizophrenia is likely to increase the penetration of these drugs in the market. Currently, second and third-generation antipsychotics capture significant market share. Pipeline drugs, undergoing clinical trials intend to block specific subtypes of serotonin and dopamine receptors which would help minimize the symptoms, modulate increased dopamine levels and further improve growth in schizophrenia market is anticipated to be primarily driven by the arrival of late-stage pipeline products, such as Intra-Cellular Therapies' ITI-007 and Alkermes' ALKS-3831 which are directed towards the treatment of negative symptoms; however, there are significant unmet needs in the schizophrenia treatment space. Poor understanding about the exact disease mechanism remains, preventing the discovery of a therapeutic breakthrough. Hence, there is a need for innovation in drug delivery technologies for the treatment of this debilitating Drugs Market Report Highlights The second-generation-antipsychotics held the largest market revenue share of 73.05% in 2024. The demand for second-generation antipsychotics in the schizophrenia drugs market is rising due to their improved safety and efficacy profiles compared to first-generation antipsychotics. The injectable antipsychotics treatment segment held the largest market revenue share in 2024. The demand for injectable antipsychotics is on the rise due to their ability to address several challenges associated with the condition. Injectable formulations, particularly long-acting injectables (LAIs), provide a steady release of medication, which helps maintain therapeutic drug levels and reduces the risk of relapse due to missed doses-a common issue with oral medications. The hospital pharmacies segment held the largest market revenue share in 2024. Hospital pharmacies are well-positioned to provide comprehensive care, including managing complex medication regimens and monitoring side effects, which are critical for this condition. North America schizophrenia drugs market held the largest market revenue share of 38.65% in 2024. It is attributable to the rising awareness and diagnosis rates of schizophrenia and related mental health disorders. This report addresses: Market intelligence to enable effective decision-making Market estimates and forecasts from 2018 to 2030 Growth opportunities and trend analyses Segment and regional revenue forecasts for market assessment Competition strategy and market share analysis Product innovation listings for you to stay ahead of the curve Why Should You Buy This Report? Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments. Competitive Landscape: Explore the market presence of key players. Future Trends: Discover the pivotal trends and drivers shaping the future of the market. Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions. Key Attributes Report Attribute Details No. of Pages 100 Forecast Period 2024-2030 Estimated Market Value (USD) in 2024 $8.19 Billion Forecasted Market Value (USD) by 2030 $11.2 Billion Compound Annual Growth Rate 5.6% Regions Covered Global Key Topics CoveredChapter 1. Methodology and ScopeChapter 2. Executive Summary2.1. Market Outlook2.2. Segment Outlook2.2.1. Drug Class and Route of Administration Outlook2.2.2. Distribution Channel Outlook2.2.3. Regional Outlook2.3. Competitive InsightsChapter 3. Schizophrenia Drugs Market Variables, Trends & Scope3.1. Market Lineage Outlook3.1.1. Parent Market Outlook3.1.2. Related/Ancillary Market Outlook3.2. Market Dynamics3.2.1. Market Driver Analysis3.2.2. Market Restraint Analysis3.3. Schizophrenia Drugs Market Analysis Tools3.3.1. Industry Analysis - Porter's3.3.1.1. Supplier Power3.3.1.2. Buyer Power3.3.1.3. Substitution Threat3.3.1.4. Threat of New Entrant3.3.1.5. Competitive Rivalry3.3.2. PESTEL Analysis3.3.2.1. Political Landscape3.3.2.2. Technological Landscape3.3.2.3. Economic Landscape3.3.3. Pricing Analysis3.3.4. Pipeline Analysis3.3.4.1. Phase 13.3.4.2. Phase 23.3.4.3. Phase 3Chapter 4. Schizophrenia Drugs Market: Drug Class Estimates & Trend Analysis4.1. Global Schizophrenia Drugs Market: Drug Class Dashboard4.2. Global Schizophrenia Drugs Market: Drug Class Movement Analysis4.3. Global Schizophrenia Drugs Market by Class, Revenue4.4. Second-Generation Antipsychotics4.5. Third-Generation Antipsychotics Chapter 5. Schizophrenia Drugs Market: Route of Administration Estimates & Trend Analysis5.1. Global Schizophrenia Drugs Market: Route of Administration Dashboard5.2. Global Schizophrenia Drugs Market: Route of Administration Movement Analysis5.3. Global Schizophrenia Drugs Market by Route of Administration , Revenue5.4. Oral Antipsychotics5.5. Injectable Antipsychotics Chapter 6. Schizophrenia Drugs Market: Distribution Channel Estimates & Trend Analysis6.1. Global Schizophrenia Drugs Market: Distribution Channel Dashboard6.2. Global Schizophrenia Drugs Market: Distribution Channel Movement Analysis6.3. Global Schizophrenia Drugs Market by Distribution Channel, Revenue6.4. Hospital Pharmacies6.5. Retail Pharmacies6.6. Online Pharmacies6.7. Others Chapter 7. Schizophrenia Drugs Market: Regional Estimates & Trend Analysis by Drug Class, Distribution Channel, and Route of Administration7.1. Regional Dashboard7.2. Market Size, & Forecasts Trend Analysis, 2018 to 20307.3. North America7.4. Europe7.5. Asia-Pacific7.6. Latin America7.7. MEA Chapter 8. Competitive Landscape8.1. Recent Developments & Impact Analysis, by Key Market Participants8.2. Company/Competition Categorization8.3. Vendor Landscape8.3.1. List of Key Distributors and Channel Partners8.3.2. Key Customers8.3.3. Key Company Market Share Analysis, 20248.3.4. Johnson & Johnson Services, Inc.8.3.5. Bristol-Myers Squibb Company/ Otsuka Holdings Co., Ltd.8.3.6. Sumitomo Pharma Co., Ltd.8.3.7. Eli Lilly and Company8.3.8. Alkermes8.3.9. VANDA PHARMACEUTICALS8.3.10. AstraZeneca8.3.11. AbbVie Inc.8.3.12. Pfizer Inc.8.3.13. H. Lundbeck A/S For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Schizophrenia Drugs Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio

Copeptin as a Prognostic Marker in Emergency Hyponatremia
Copeptin as a Prognostic Marker in Emergency Hyponatremia

Medscape

time33 minutes ago

  • Medscape

Copeptin as a Prognostic Marker in Emergency Hyponatremia

TOPLINE: Measuring copeptin levels in patients with hypotonic hyponatremia on emergency department (ED) admission provided key diagnostic insights. The copeptin to urinary sodium ratio more accurately predicted preserved extracellular fluid (ECF) than urinary sodium alone, and higher copeptin levels were linked to an increased risk for mortality. METHODOLOGY: Hypotonic hyponatremia is frequently observed during hospitalization and can increase the risk for mortality; in this context, copeptin, the C-terminal portion of the arginine vasopressin precursor, has emerged as a valuable marker for predicting complications associated with hypotonic hyponatremia. Researchers reported findings from a prospective cohort study conducted between June 2018 and August 2019 at a hospital in Italy, evaluating the accuracy of copeptin in identifying preserved ECF patterns and its predictive value in critically ill patients admitted to the ED. They included 84 adult patients (median age, 79 years; 47 women), in whom hyponatremia was confirmed by both direct and indirect ion-selective electrode assays after glucose correction; severe hyponatremia was observed in 34.5% of patients. Information on vital signs, ultrasound, medical history, and comorbidities was recorded, and pretreatment blood and urine samples were collected for laboratory analyses. ECF status was reassessed after discharge by three independent endocrinologists; in-hospital mortality and 6-month mortality were also evaluated. TAKEAWAY: Reduced ECF, increased ECF, and preserved ECF were reported in 28 patients each. A ratio of copeptin to urinary sodium of ≤ 29.5 pmol/mmol × 100 increased the likelihood of preserved ECF by more than fourfold (adjusted odds ratio, 4.28; P = .026), outperforming standard urinary sodium measurements (difference in area under the curve when the urinary sodium cut-off was > 30 mmol/L, 0.177; P = .013). Copeptin levels were positively associated with increased risks for in-hospital mortality (P < .0001) and 6-month mortality (P = .02), with levels above 13.6 pmol/L associated with a more than fourfold increased risk for 6-month mortality (hazard ratio, 4.507; P = .0001). Additional predictors of 6-month mortality included levels of N-terminal prohormone of brain natriuretic peptide (P = .031) and comorbidity burden (P = .009). IN PRACTICE: 'It is important to note that our results do not suggest replacing copeptin with other established clinical and biochemical evaluations routinely performed in emergency care, such as s-K [serum potassium] or NT-proBNP [N-terminal prohormone of brain natriuretic peptide] levels, when clinically appropriate. Rather, the aim of adjusting copeptin's predictive value for these common parameters in our analysis was to confirm its independent contribution,' the authors wrote. SOURCE: This study was led by Alessandro Maria Berton, Department of Medical Sciences, University of Turin, Turin, Italy. It was published online in The Journal of Clinical Endocrinology and Metabolism. LIMITATIONS: Patient recruitment was restricted to daytime hours and weekdays, thus limiting the generalizability. Certain analytes were not available for all patients during ED evaluation. Additional urinary parameters such as urine chloride, uric acid fractional excretion, and potassium levels were not compared with the copeptin/urinary sodium index. DISCLOSURES: This study received no specific grant from any funding agency. The authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

LGA says tackling child obesity essential to avoid ticking health time bomb
LGA says tackling child obesity essential to avoid ticking health time bomb

Yahoo

timean hour ago

  • Yahoo

LGA says tackling child obesity essential to avoid ticking health time bomb

Children who are obese today could become obese adults in the future. The warning comes from Councillor David Fothergill, chairman of the Local Government Association's (LGA) Community Wellbeing Board, in response to a Royal Society for Public Health report on physical activity and child obesity. Cllr Fothergill said: "As these stark new projections show, there is still much to do if we are to avoid today's obese children becoming tomorrow's obese adults. "The government must work with councils and others to turbo charge the efforts to tackle this ticking health time bomb, so we can collectively tackle sedentary lifestyles and boost physical activity." He emphasised the challenges faced by families, especially in disadvantaged areas. READ: Obesity remains a 'significant health challenge' as latest figures revealed Cllr Fothergill said: "Access to healthy, nutritious food is a huge challenge for families in our most disadvantaged communities, particularly amidst the ongoing rise in the cost-of-living. To effectively tackle obesity, councils need funding to provide targeted support to those who need it the most." He also called for funding from the soft drinks industry levy to be reinvested in council-run healthy eating and physical activity programmes. Cllr Fothergill said: "It is vital that councils are adequately funded through the public health grant to provide the frontline services that tackle obesity, so we were concerned the Spending Review once again overlooked public health funding. Investment in councils' public health services now will reap benefits for everyone longer-term and help improve the life chances of the next generation."

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store